Trial Radar KI
Die klinische Studie NCT02807272 (CMML/AML) für Leukämie, Myelomonozytisch, Chronisch ist abgeschlossen. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (CMML/AML) Phase 2 44

Abgeschlossen
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT02807272 (CMML/AML) untersuchte Behandlung im Zusammenhang mit Leukämie, Myelomonozytisch, Chronisch. Diese interventionsstudie der Phase 2 hat den Status abgeschlossen. Die Studie begann am 10. Januar 2017 mit 44 Teilnehmern. Sie wurde durchgeführt von Kura Oncology und am 30. November 2020 abgeschlossen. Die Daten von ClinicalTrials.gov wurden zuletzt am 17. Juli 2024 aktualisiert.
Kurzbeschreibung
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic Myelomonocytic Leukemia (CMML), and 36 eligible subjects with Acute Myeloid Leukemia (AML). Subjects received tipifarnib 1200 mg to be taken orally with food, twice daily, for 7 days in alternat...Mehr anzeigen
Ausführliche Beschreibung
This Phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN cohorts) and Acute Myeloid Leukemia (AML cohorts). For MDS/MPN cohorts, this study will assess the antitumor activity of tipifarnib, in terms of ORR, in subjects with MDS/MPN, including CMML, who have a high ratio of expression of CXCR4 to CXCR2 (CXCR4/2 rati...Mehr anzeigen
Offizieller Titel

A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia

Erkrankungen
Leukämie, Myelomonozytisch, Chronisch
Weitere Studien-IDs
  • CMML/AML
  • KO-TIP-004
NCT-Nummer
NCT02807272
Studienbeginn (tatsächlich)
2017-01-10
Zuletzt aktualisiert
2024-07-17
Studienende (vorauss.)
2020-11-30
Geplante Rekrutierung
44
Studientyp
Interventionsstudie
PHASE
Phase 2
Status
Abgeschlossen
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellTipifarnib, Oral
Single arm
Tipifarnib
Oral tablet
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Objective Response Rate (ORR)
The ORR was estimated based on the number of participants who achieved an objective response (OR) (complete response \[CR\], complete cytogenetic remission \[CCR\], partial remission \[PR\], marrow response \[MR\], or clinical benefit \[CB\] performed by Principal Investigator according to the MDS/MPN International Working Group \[IWG\] criteria).
Up to 12 months
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Duration of Response (DoR)
DoR was measured from the date the participant first met the criteria of an OR to the date that the participant progressed or until death from any cause during the period of disease assessments. Participants without progression or death were censored at the date of the last disease assessment. Participants who received subsequent anticancer therapy were censored at the date of last disease assessment before subsequent anticancer therapy. The median duration of response and corresponding 95% CI was estimated using the Kaplan Meier method.
Up to approximately 15 months
Progression Free Survival (PFS)
The PFS time was defined as the time from the date of consent signed to the date of documented disease progression or death due to any cause, whichever occurred first. Participants without progression or death were censored at the date of the last disease assessment. Participants who received subsequent anticancer therapy were censored at the date of the last disease assessment before subsequent anticancer therapy. The Kaplan-Meier product-limit method was used to estimate the 1-year PFS rate, as well as the corresponding 95% CI.
1 year
Overall Survival (OS)
OS time was defined as the time from the date of consent signed to the date of death due to any cause. Participants who were alive or lost to follow-up by the end of the study were censored at the date last known to be alive. The Kaplan-Meier method was used to estimate the proportion (%) of subjects without an event at 12 months, as well as their corresponding 95% CI.
Up to approximately 15 months
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with it. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE severity was rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03.: grade 1(mild), grade 2(moderate), grade 3(severe), grade 4(life-threatening), grade 5(death). An AE was considered serious if resulted in any of the following: death, life-threatening, caused inpatient hospitalization or prolonged it, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital abnormality/birth defect, or was an important medical event.
Up to approximately 3 years
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle

  1. Subject is at least 18 years of age.

  2. For subjects to be enrolled in the CMML or MDS/MPN cohorts:

    a. Diagnosis of CMML or MDS/MPN as defined by the World Health Organization (WHO) criteria (2008).

  3. For subjects enrolled in the AML cohort:

    1. Documented pathological evidence of AML, as defined by WHO criteria (2008)
    2. Refractory to previous induction chemotherapy, relapsed disease, or age ≥ 60 and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.

  5. Subject is willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures (including bone marrow assessments).

  6. At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 14. Subjects must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the Investigator.

  7. Acceptable liver function:

    1. Total bilirubin ≤ upper limit of normal (ULN).
    2. AST (SGOT) and ALT (SGPT) ≤ 1.5 x ULN.

  8. Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease formulas.

  9. Female subjects must be:

    1. Of non-child-bearing potential (surgically sterilized or at least 2 years post-menopausal); or
    2. If of child-bearing potential, subject must use a highly effective method of contraception, such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence. Both females and male subjects with female partners of child-bearing potential must agree to use a highly effective method of contraception for 2 weeks prior to screening, during, and at least 28 days after last dose of trial medication for females and 90 days for males. Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of trial medication.
    3. And, not breast feeding at any time during the study.

  10. Written and voluntary informed consent understood, signed and dated.

  1. Neoplasia harbours RAS mutation (NRAS mutant, KRAS mutant or double mutant)
  2. Acute promyelocytic leukemia or Bcr-Abl positive leukemia (chronic myelogenous leukemia in blast crisis)
  3. Clinically active CNS leukemia
  4. CMML with t(5;12) that have not yet received imatinib.
  5. Participation in any interventional study within 1 week of randomization or 5 half-lives of the prior treatment agent (whichever is longer).
  6. Ongoing treatment with an anticancer agent for CMML, MDS/MPN or AML not contemplated in this protocol. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 14.
  7. Hematopoietic stem cell transplantation (HSCT) performed within 3 months prior to Cycle 1 Day 1.
  8. Concurrent use of granulocyte macrophage colony-stimulating factor (GM-CSF).
  9. Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase inhibitor.
  10. Active coronary artery disease requiring treatment, myocardial infarction within the prior year, New York Heart Association grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.
  11. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
  12. Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).
  13. Active and uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.
  14. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
  15. The subject has legal incapacity or limited legal capacity.
  16. Significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason.
Kura Oncology, Inc. logoKura Oncology
Keine Kontaktdaten vorhanden
8 Studienstandorte in 1 Ländern

Arizona

Mayo Clinic Arizona, Scottsdale, Arizona, 85054, United States

Florida

Mayo Clinic Florida, Jacksonville, Florida, 32224, United States
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, 33612, United States

Maryland

Johns Hopkins University, Baltimore, Maryland, 21231, United States

Minnesota

Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States

New York

Weill Cornell Medicine, New York, New York, 10065, United States

Ohio

Cleveland Clinic, Cleveland, Ohio, 44195, United States

Pennsylvania

University of Pennsylvania Hospital, Philadelphia, Pennsylvania, 19104, United States